Organovo, Inc.
(https://organovo.com) 📸 Data Snapshot: May 25, 2026Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.
The heading fluff saturation is moderate, using power words like Pioneering and Exceptional without immediate data support. While the Pipeline page contains technical substance regarding FXR314 and Phase 2 trials, the Homepage and About pages are extremely thin, with the latter containing only 167 characters of navigation markers. Substantial temporal rot exists; the site references medicinal chemistry plans for 2023 and an IND expectation for 2025, which, relative to the May 2026 anchor, indicates unmaintained content.
Information Density is read straight from the body copy: how much of the text carries grounded, checkable substance versus hollow filler. Below is the clean text the engine analyzed, then the industry’s known generic-claim patterns to weigh it against.
📝 The Narrative — clean text per page (the substance-vs-filler signal)
HOMEPAGE · THIN (https://organovo.com) Home – Organovo, Inc.
[H1] Pioneering 3D Human Tissues for Drug Discovery [IMG: News Icon] [H2] News Apr 23 | 2025 [H3] VivoSim to Carry Forward Organovo 3D Bioprinting Read More »Apr 02 | 2025 [H3] Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements Read More »Mar 27 | 2025 [H3] Organovo Provides Business Update Read More »
SUB-PAGE · THIN (https://organovo.com/about/) About – Organovo, Inc.
[IMG: logo] About Our Story Who We Are Leadership Team Board of Directors Pipeline Overview Publications News & Events Media Coverage Careers Contact
SUB-PAGE (https://organovo.com/pipeline/) Pipeline – Organovo, Inc.
[H2] We Are Focused on the Rapid Clinical and Commercial Development of New Medicines Based on Our Exceptional 3D Human Tissue Model Technology. Organovo Has FDA Approval for FXR314 for Phase 2 Clinical Trial in Ulcerative Colitis Organovo has an FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis for its lead therapeutic molecule FXR314. We have advanced our proprietary 3D human tissue models to support the most effective clinical development strategy for FXR314 and the treatment of inflammatory bowel diseases including Crohn’s Disease. FXR314 also has potential applications in the treatment of metabolic disease and oncology. FXR314, has shown, in initial clinical trials, to be a possible best-in-class FXR agonist that is delivered orally, with high potency, safety, tolerability and the potential to avoid dose-limiting toxicity issues found in other FXR targeted compounds. FXR314 has received FDA clinical trial authorization for a Phase 2 trial in ulcerative colitis. Organovo is also advancing FXR314 for the treatment of other Inflammatory Bowel Diseases including Crohn’s Disease as well as diseases of the Liver including NASH and Primary Biliary Cholangitis. Organovo expects FXR314 to have a widening set of therapeutic applications as we advance our knowledge and our science. In addition to FXR314, Organovo is planning to begin medicinal chemistry in 2023 to create a novel drug for another, as yet undisclosed, target. The target was validated in our 3d tissue models of Crohn’s disease. We expect the drug created to have an IND by the end of 2025. ProgramIndicationDiscoveryPhase 1Phase 2/3Areas of Clinical Focus FXR314Inflammatory Bowel Disease Ulcerative Colitis Novel Drug to Undisclosed TargetInflammatory Bowel DiseaseIND Expected 2025 Crohn’s Disease FXR314Liver FibrosisPhase 2 Ready. Seeking Development Partner NASH & Primary Biliary CholangitisDiscoveryPhase 1Phase 2/3 FXR314 — Inflammatory Bowel Disease Areas of Clinical Focus: Ulcerative Colitis Novel Drug to Undisclosed Target — Inflammatory Bowel DiseaseIND Expected 2025 Areas of Clinical Focus: Crohn’s Disease FXR314 — Liver FibrosisPhase 2 Ready. Seeking Development Partner Areas of Clinical Focus: NASH & Primary Biliary Cholangitis
SUB-PAGE · THIN (https://organovo.com/news-events/) News & Events – Organovo, Inc.
[H2] Upcoming Events There are no upcoming events at this time [H2] Recent Press Releases Apr 23, 2025 [H3] VivoSim to Carry Forward Organovo 3D Bioprinting Apr 02, 2025 [H3] Organovo Provides Update on Cash and Nasdaq Continued Listing Requirements [H2] Recent Media May 6, 2019 [H3] Organovo: Bioprinting Could be the New Solution to Organ Transplantation Oct 19, 2018 [H3] 3D Method Uses Patients' Own Cells to Repair Tissue Damage
🧭 Industry Context — common generic-claim patterns in Medical Devices, Pharma & Biotech to weigh the text against
This page presents a snapshot of public data from Organovo, Inc., captured on May 25, 2026, to show how machine logic reads Information Density signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to Organovo, Inc.: This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://organovo.com to view the most current version of its content and see directly what this company is about and what it offers.